Research and development spending for the quarter ended December 31, 2010 was $14.0 million, compared to $11.4 million for 2009. The increase in expense results principally from the commencement of start-up activities related to the phase III XIAFLEX clinical trials for Peyronie's disease and costs related to development of a larger scale XIAFLEX production process.
Selling, general and administrative costs for the quarter ended December 31, 2010 were $47.0 million, compared to $38.7 million in the comparable 2009 period. The increase was primarily due to the addition of the sales and reimbursement field force and infrastructure, and promotional and training activity in support of the launch of XIAFLEX for Dupuytren's in the U.S., and higher non-cash stock-based compensation expense.
As of December 31, 2010, Auxilium had $128.2 million in cash, cash equivalents and short-term investments, compared to $142.4 million at September 30, 2010.
2010 Revenue DetailsAuxilium reported the following unaudited net revenues (all amounts in millions of dollars) for the full year 2010: Year EndYear EndIncrease12/31/201012/31/2009 (Decrease)Testim U.S. Revenue
$190.0$152.025%Testim Ex – U.S. & Contract Revenue
3.08.5(64%)Total Testim Revenue
$193.0$160.520%XIAFLEX U.S. Revenue
$14.1-n/aXIAFLEX Contract Revenue
4.33.622%Total XIAFLEX Revenue
$18.4$3.6417%Total Worldwide Revenue
$211.4$164.029%Contract Revenues represent amortization of previously receive
|SOURCE Auxilium Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved